Morgan Stanley’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $188K | Sell |
20,093
-12,761
| -39% | -$121K | ﹤0.01% | 5977 |
|
|
2026
Q1 | $308K | Buy |
32,854
+10,473
| +47% | +$88.2K | ﹤0.01% | 5687 |
|
|
2025
Q4 | $182K | Sell |
22,381
-132,461
| -86% | -$1.63M | ﹤0.01% | 5965 |
|
|
2025
Q3 | $1.96M | Sell |
154,842
-4,157
| -3% | -$39.5K | ﹤0.01% | 4807 |
|
|
2025
Q2 | $1.1M | Buy |
158,999
+82,388
| +108% | +$598K | ﹤0.01% | 5048 |
|
|
2025
Q1 | $407K | Buy |
76,611
+14,980
| +24% | +$132K | ﹤0.01% | 5423 |
|
|
2024
Q4 | $727K | Sell |
61,631
-93,115
| -60% | -$1.56M | ﹤0.01% | 5248 |
|
|
2024
Q3 | $3.19M | Sell |
154,746
-102,889
| -40% | -$5.27M | ﹤0.01% | 4320 |
|
|
2024
Q2 | $11.7M | Buy |
257,635
+85,659
| +50% | +$3.6M | ﹤0.01% | 3198 |
|
|
2024
Q1 | $6.75M | Buy |
171,976
+169,919
| +8,261% | +$4.19M | ﹤0.01% | 3664 |
|
|
2023
Q4 | $12.4K | Sell |
2,057
-1,232
| -37% | -$6.61K | ﹤0.01% | 6585 |
|
|
2023
Q3 | $22.2K | Hold |
3,289
| – | – | ﹤0.01% | 6449 |
|
|
2023
Q2 | $25.8K | Sell |
3,289
-326
| -9% | -$2.93K | ﹤0.01% | 6478 |
|
|
2023
Q1 | $26.3K | Buy |
3,615
+834
| +30% | +$3.65K | ﹤0.01% | 6528 |
|
|
2022
Q4 | $9.22K | Sell |
2,781
-2,047
| -42% | -$7.88K | ﹤0.01% | 6972 |
|
|
2022
Q3 | $23K | Buy |
4,828
+367
| +8% | +$2.59K | ﹤0.01% | 6725 |
|
|
2022
Q2 | $35K | Buy |
4,461
+450
| +11% | +$4.35K | ﹤0.01% | 6768 |
|
|
2022
Q1 | $64K | Sell |
4,011
-65,390
| -94% | -$866K | ﹤0.01% | 6571 |
|
|
2021
Q4 | $1.28M | Sell |
69,401
-19,592
| -22% | -$531K | ﹤0.01% | 4902 |
|
|
2021
Q3 | $2.72M | Buy |
88,993
+2,589
| +3% | +$102K | ﹤0.01% | 4316 |
|
|
2021
Q2 | $4.74M | Sell |
86,404
-45,656
| -35% | -$2.53M | ﹤0.01% | 3832 |
|
|
2021
Q1 | $7.8M | Buy |
132,060
+107,024
| +427% | +$7.04M | ﹤0.01% | 2908 |
|
|
2020
Q4 | $939K | Buy |
25,036
+552
| +2% | +$20.6K | ﹤0.01% | 4706 |
|
|
2020
Q3 | $1.32M | Sell |
24,484
-20,365
| -45% | -$3.69M | ﹤0.01% | 4006 |
|
|
2020
Q2 | $11.3M | Buy |
44,849
+19,048
| +74% | +$3.85M | ﹤0.01% | 1865 |
|
|
2020
Q1 | $4.06M | Sell |
25,801
-397
| -2% | -$67.1K | ﹤0.01% | 2654 |
|
|
2019
Q4 | $4.29M | Sell |
26,198
-3,955
| -13% | -$585K | ﹤0.01% | 3360 |
|
|
2019
Q3 | $4.41M | Sell |
30,153
-891
| -3% | -$155K | ﹤0.01% | 2997 |
|
|
2019
Q2 | $6.45M | Sell |
31,044
-373
| -1% | -$79.9K | ﹤0.01% | 2653 |
|
|
2019
Q1 | $6.55M | Buy |
31,417
+1,369
| +5% | +$302K | ﹤0.01% | 2448 |
|
|
2018
Q4 | $5.26M | Buy |
30,048
+646
| +2% | +$129K | ﹤0.01% | 2851 |
|
|
2018
Q3 | $6.66M | Buy |
29,402
+5,857
| +25% | +$947K | ﹤0.01% | 2868 |
|
|
2018
Q2 | $3.57M | Buy |
23,545
+2,866
| +14% | +$521K | ﹤0.01% | 3545 |
|
|
2018
Q1 | $3.78M | Buy |
20,679
+2,016
| +11% | +$453K | ﹤0.01% | 3351 |
|
|
2017
Q4 | $3.98M | Buy |
18,663
+15,445
| +480% | +$3.31M | ﹤0.01% | 3340 |
|
|
2017
Q3 | $691K | Sell |
3,218
-415
| -11% | -$81.2K | ﹤0.01% | 4676 |
|
|
2017
Q2 | $686K | Buy |
3,633
+1,004
| +38% | +$197K | ﹤0.01% | 4618 |
|
|
2017
Q1 | $651K | Buy |
2,629
+790
| +43% | +$194K | ﹤0.01% | 4673 |
|
|
2016
Q4 | $467K | Buy |
1,839
+842
| +84% | +$193K | ﹤0.01% | 4975 |
|
|
2016
Q3 | $203K | Buy |
997
+110
| +12% | +$13.7K | ﹤0.01% | 5015 |
|
|
2016
Q2 | $80K | Buy |
887
+710
| +401% | +$55.7K | ﹤0.01% | 5343 |
|
|
2016
Q1 | $10K | Sell |
177
-33
| -16% | -$1.46K | ﹤0.01% | 6126 |
|
|
2015
Q4 | $10K | Sell |
210
-140
| -40% | -$7.13K | ﹤0.01% | 6236 |
|
|
2015
Q3 | $17K | Buy |
350
+172
| +97% | +$11.5K | ﹤0.01% | 6093 |
|
|
2015
Q2 | $16K | Buy |
+178
| New | +$17.9K | ﹤0.01% | 6187 |
|
Other funds holding CRBP
CAM
O
JHC
PM
SCM
ACM
Morgan Stanley's CRBP Position: Q2 2026 in Review
Morgan Stanley reduced its Corbus Pharmaceuticals (CRBP) stake by 39% in Q2 2026, selling an estimated $121K and leaving 20,093 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #5977.
Morgan Stanley first reported a position in CRBP in Q2 2015 and has held it in 45 quarters since. The position peaked at $11.7M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.
- Morgan Stanley held 20,093 shares of Corbus Pharmaceuticals worth $188K as of Q2 2026.
- Morgan Stanley sold 12,761 Corbus Pharmaceuticals shares in Q2 2026, an estimated $121K.
- Corbus Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5977 holding.
- Morgan Stanley first reported a position in Corbus Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
- Morgan Stanley's Corbus Pharmaceuticals position peaked at $11.7M in Q2 2024.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.